New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

References

• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
   PubMed Web of Science ®Google Scholar
• Gleevec (imatinib) [package insert]. East Hanover, NJNovartis Pharmaceuticals Corp.
   Google Scholar
• Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
   PubMed Web of Science ®Google Scholar
• Shah NP. Medical management of CML. Hematology Am Soc Hematol Educ Program 2007;371–375.
   PubMedGoogle Scholar
• Deininger MW. Optimizing therapy of chronic myeloid leukemia. Exp Hematol 2007;35(Suppl. 1):144–154.
   PubMed Web of Science ®Google Scholar
• Zhang WW, Cortes JE, Yao H, et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009;27:3642–3649.
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374–7379.
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nager B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117–125.
   PubMed Web of Science ®Google Scholar
• Ernst T, Erben P, Muller MC, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008;93:186–192.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112:53–55.
   PubMed Web of Science ®Google Scholar
• Modugno M, Casale E, Soncini C, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007;67:7987–7990.
   PubMed Web of Science ®Google Scholar
• Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009;114:4944–4953.
   PubMed Web of Science ®Google Scholar
• Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutation in imatinib-naïve patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128–2137.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Anand M, Marin D, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 2006;20:658–663.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 2.2010. Available from: www.nccn.org/ .
   Google Scholar
• Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR-ABL-transformed hematopoietic cell lines. Blood 2000;95:3498–3505.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571; diverse mechanisms of resistance. Blood 2000;96:1070–1079.
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95: 1758–1766.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004;18:1321–1331.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Larson RA, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551–560.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154–2560.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematology and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia. Results of a phase 2 study. Blood 2002;99:1928–1937.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754–4759.
   PubMed Web of Science ®Google Scholar
• Cortes J, Baccarani M, Guilhot F, et al. A phase III randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010;28:424–430.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Druker BJ, Cortes-Franco J, et al. 24 months update of the TOPS study: a phase III, randomized, open-label study of 400 mg/d (SD-IM) versus 800 mg/d (HD-IM) of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP). Blood 2009;114(Suppl. 1): Abstract 337.
   Google Scholar
• Hehlmann R, Lauseker M, Jung-Munkqitz S, et al. Treatment optimization by high-dose imatinib: randomized comparison of imatinib 800 mg versus imatinib 400 mg +/− IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: the German CML-study IV. J Clin Oncol 2010;28(Suppl.): Abstract 6517.
   PubMed Web of Science ®Google Scholar
• Sprycel (dasatinib) [package insert]. Princeton, NJBristol-Myers Squibb Co.
   Google Scholar
• Saglio G, Cortes JE, Schiffer CA, et al. Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy. J Clin Oncol 2010;28(Suppl.): Abstract 6569.
   PubMed Web of Science ®Google Scholar
• Frame D. New strategies in controlling drug resistance in chronic myeloid leukemia. Am J Health-Syst Pharm 2007;64:S16–S21.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–4505.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303–2309.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2002;22:1200–1206.
   Web of Science ®Google Scholar
• Cervantes F, Baccarani M, Lipton J, et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a two-year update of the START-C study. Haematologica 2008;93(Suppl. 1): Abstract 0934.
   Google Scholar
• Kantarjian H, Pasquini R, Levy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 mg daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:4136–4147.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204–3212.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim S, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieve rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia in patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95: 232–240.
   PubMed Web of Science ®Google Scholar
• Shah NP, Cortes JE, Schiffer CA, et al. Four-year follow-up of patients with chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. J Clin Oncol 2010;28(Suppl.): Abstract 6512.
   Google Scholar
• Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322–6329.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005;11:4941–4947.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129–141.
   PubMed Web of Science ®Google Scholar
• Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib, dasatinib. Leuk Lymphoma 2008;49:615–619.
   PubMed Web of Science ®Google Scholar
• Tasigna (nilotinib) [package insert]. East Hanover, NJNovartis Pharmaceuticals Co.
   Google Scholar
• Kantarjian H, Giles F, Bhalla K, et al. Update on imatinib- resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes. Blood 2009;114(Suppl. 1): Abstract 1129.
   Google Scholar
• Hochhaus A, Giles F, Apperely J, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24 month follow-up results of a phase 2 study. Haematologica 2009;94(Suppl.): Abstract 0631.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392–397.
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Palandri F, et al. Nilotinib 800 mg daily as frontline therapy of Ph+ chronic myeloid leukemia: dose delivered and safety profile for the GIMEMA CML working party. Blood 2009;114(Suppl. 1): Abstract 2205.
   Google Scholar
• O'Dwyer M, Kent E, Parker M, et al. Nilotinib 300 mg twice daily is effective and well tolerated as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: preliminary results of the ICORG 0802 Phase 2 study. Blood 2009;114(Suppl. 1): Abstract 3294.
   Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;262:2251–2259.
   Web of Science ®Google Scholar
• Hino M, Matsumura I, Kurokawa M, et al. The effect of nilotinib on major molecular response (MMR) compared with imatinib in Japanese patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from the Japanese subset of ENESTnd. J Clin Oncol 2010;28(Suppl.): Abstract e17001.
   Google Scholar
• Tasigna (nilotinib) [package insert]. East Hanover, NJNovartis
   Google Scholar
• Gambacorti-Passerini C, Cortes JE, Khoury HJ, et al. Safety and efficacy of bosutinib in patients with AP and BP CML and Ph+ ALL following resistance/intolerance to imatinib and other TKIs: update from study SKI-200. J Clin Oncol 2010;28(Suppl.): Abstract 6509.
   Google Scholar
• Cortes JE, Kantarjian H, Brummendorf T, et al. Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). J Clin Oncol 2010;28(Suppl.): Abstract 6502.
   Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009;115:5382–5393.
   PubMed Web of Science ®Google Scholar
• Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addition in chronic myelogenous leukemia. Cancer Res 2006;66:10959–10966.
   PubMed Web of Science ®Google Scholar
• Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009;23:1446–1454.
   PubMed Web of Science ®Google Scholar
• Cortes-Franco J, Khoury HJ, Nicolini FE, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation- results of an ongoing multicenter phase 2/3 study. Blood 2009;114(Suppl. 1): Abstract 644.
   Google Scholar
• Lipton JH, Wetzler M, Nicolini F, et al. Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): analysis of two phase II studies. J Clin Oncol 2010;28(Suppl.): Abstract 6568.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Cortes JE, Deininger MW, et al. Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies. J Clin Oncol 2010;28(Suppl.): Abstract 6511.
   Google Scholar
• Cortes-Franco J, Dombret H, Schafhausen P, et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 2009;114(Suppl. 1): Abstract 864.
   Google Scholar
• Van Etten RA, Chan WW, Zaleskas VM, et al. DCC-2036: A novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. Blood 2007;110(Suppl. 1): Abstract 463.
   Google Scholar
• Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988;319:990–998.
   PubMed Web of Science ®Google Scholar
• Carpiuc KT, Stephens JM, Botteman MF, Feng W, Hay JW. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother 2007;8:2775–2787.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1042.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965–1971.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Cancer 2007;109:2068–2076.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimingo G, et al. Imatinib plus steroids induces complete remission and prolonged survival in elderly Philadelphia chromosome positive acute lymphoblastic leukemia without additional chemotherapy: results of the Grippo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-protocol. Blood 2007;109:3676–3678.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396–4407.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O'Brien SM, Faderl S, et al. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph-ALL). J Clin Oncol 2010;28(Suppl.): Abstract 6506.
   Google Scholar
• Towatari M, Yanada M, Usui N, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004;104:3507–3512.
   PubMed Web of Science ®Google Scholar
• Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006;20:1526–1532.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006;108:1469–1477.
   PubMed Web of Science ®Google Scholar
• De Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109:1408–1413.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. First results of the GRAAPH-2005 study in younger adult patients with de novo Philadelphia positive acute lymphoblastic leukemia. Blood 2008;112(Suppl. 1): Abstract 12.
   Google Scholar
• Ottmann OG, Wassmann B. Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: current status and evolving concepts. Best Pract Res Clin Haematol 2003;15:757–769.
   Web of Science ®Google Scholar
• Hoffmann WK, Komor M, Hoelzer D, Ottmann OG. Mechanisms of resistance to STI571 (imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 2004;45:655–660.
   PubMed Web of Science ®Google Scholar
• Jones D, Thomas D, Cameron Yin C, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge alter therapy with BCR-ABL kinase inhibitors. Cancer 2008;113:985–994.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Scheuring U, Pfeifer H, et al. Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-a (IFN-a) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Leukemia 2003;17:1919–1924.
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal chemotherapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995;86:2091–2097.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547–561.
   PubMed Web of Science ®Google Scholar
• Petzer AL, Gunsilius E, Hayes M, et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002;117:623–625.
   PubMed Web of Science ®Google Scholar
• Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002;119:106–108.
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110:2309–2315.
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Guarini A, et al. Line treatment of adult Ph+ acute lymphoblastic leukemia (ALL) patients. Final results of the GIMEMA LAL1205 study. Blood 2008;112(Suppl. 1): Abstract 305.
   Google Scholar
• Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol 2010;85:164–170.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Cayuela JM, Recher C, et al. Dasatinib (Sprycel) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL: results of the first 22 patients included in the EWALL-Ph-01 trial (on behalf of the European Working Group on Adult ALL (EWALL)). Blood 2008;112(Suppl. 1): Abstract 2920.
   Google Scholar
• Ravandi F, Kantarjian H, Thomas DA, et al. Phase II study of combination of the hypercvad regimen with dasatinib in the front line therapy of patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Blood 2009;114(Suppl. 1): Abstract 837.
   Google Scholar
• Ravandi F, Kantarjian H, Cortes J, et al. Combinations of the hypercvad regimen with dasatinib is effective in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia and lymphoid blast phase chronic myeloid leukemia (CML-LB). Blood 2009;114(Suppl. 1): Abstract 2043.
   Google Scholar